CYP2C9 Ile359 and Leu359 variants:: enzyme kinetic study with seven substrates

被引:231
作者
Takanashi, K
Tainaka, H
Kobayashi, K
Yasumori, T
Hosakawa, M
Chiba, K
机构
[1] Chiba Univ, Fac Pharmaceut Sci, Lab Biochem Pharmacol & Toxicol, Inage Ku, Chiba 2638522, Japan
[2] Asahi Techno Glass Corp, Chiba, Japan
[3] Keio Univ, Sch Med, Dept Pharmacol, Shinjuku Ku, Tokyo 160, Japan
来源
PHARMACOGENETICS | 2000年 / 10卷 / 02期
关键词
CYP2C9; polymorphism; allele-specific expression;
D O I
10.1097/00008571-200003000-00001
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
To assess the effects of Ile(359) to Leu(359) change on CYP2C9-mediated metabolism, we performed site-directed mutagenesis and cDNA expression in yeast for CYP2C9 and examined in detail the kinetics of seven metabolic reactions by wild-type CYP2C9 (Ile359) and its Leu(359) variant. For the metabolism of all the substrates studied, the Leu(359) Variant exhibited smaller V-max/K-m values than did the wild-type. The differences in the Vmax/Km values between the wild-type and the Leu(359) variant varied from 3.4-fold to 26.9-fold. The Leu(359) variant had higher K-m values than did the wild-type for all the reactions studied. Among the seven reactions studied, the greatest difference in the V-max values between the wild-type and the Leu(359) variant was for piroxicam 5'-hydroxylation (408 versus 19 pmol/ min/nmol P450), whereas there were no differences in the V-max values between the wildtype and the Leu(359) Variant for diclofenac 4'-hydroxylation and tolbutamide methylhydroxylation, These results indicate that the Ile(359) to Leu(359) change significantly decreases the catalytic activity of all the CYP2C9-mediated metabolisms studied, whereas the extent of the reduction in activity and changes of the kinetic parameters varies between substrates, Moreover, the amino acid substitution decreased the enantiomeric excess in the formation of 5-(4-hydroxyphenyl)-5-phenylhydantoin from phenytoin, Pharmacogenetics 10:95-104 (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:95 / 104
页数:10
相关论文
共 38 条
[1]  
Bajpai M, 1996, DRUG METAB DISPOS, V24, P1401
[2]   Allelic and functional variability of cytochrome P4502C9 [J].
Bhasker, CR ;
Miners, JO ;
Coulter, S ;
Birkett, DJ .
PHARMACOGENETICS, 1997, 7 (01) :51-58
[3]   Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-K-m catalysts of cyclophosphamide and ifosfamide activation [J].
Chang, TKH ;
Yu, L ;
Goldstein, JA ;
Waxman, DJ .
PHARMACOGENETICS, 1997, 7 (03) :211-221
[4]  
FRITZ S, 1987, J PHARMACOL EXP THER, V241, P615
[5]   HIGH-LEVEL EXPRESSION OF HUMAN LIPOCORTIN-I IN THE FISSION YEAST SCHIZOSACCHAROMYCES-POMBE USING A NOVEL EXPRESSION VECTOR [J].
GIGAHAMA, Y ;
TOHDA, H ;
OKADA, H ;
OWADA, MK ;
OKAYAMA, H ;
KUMAGAI, H .
BIO-TECHNOLOGY, 1994, 12 (04) :400-404
[6]   BIOCHEMISTRY AND MOLECULAR-BIOLOGY OF THE HUMAN CYP2C SUBFAMILY [J].
GOLDSTEIN, JA ;
DEMORAIS, SMF .
PHARMACOGENETICS, 1994, 4 (06) :285-299
[7]  
GOTOH O, 1992, J BIOL CHEM, V267, P83
[8]   Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms [J].
Haining, RL ;
Hunter, AP ;
Veronese, ME ;
Trager, WF ;
Rettie, AE .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1996, 333 (02) :447-458
[9]  
KAMINSKY LS, 1993, MOL PHARMACOL, V43, P234
[10]   PURIFICATION OF HUMAN-LIVER CYTOCHROME-P-450 CATALYZING TESTOSTERONE 6-BETA-HYDROXYLATION [J].
KAWANO, S ;
KAMATAKI, T ;
YASUMORI, T ;
YAMAZOE, Y ;
KATO, R .
JOURNAL OF BIOCHEMISTRY, 1987, 102 (03) :493-501